Suraxavir marboxil (formerly known as S-033188) is a prodrug of suraxavir, an antiviral agent that inhibits the cap-dependent endonuclease of the influenza A and B viruses, thereby blocking viral replication. It is structurally similar to baloxavir marboxil but was developed to offer improved pharmacokinetics and antiviral potency. Suraxavir marboxil demonstrates strong in vitro activity against a broad range of influenza strains, including those resistant to neuraminidase inhibitors. In vivo studies have shown that it significantly reduces viral load and improves survival rates in infected animal models. Its long half-life allows for single-dose administration, making it a promising candidate for both treatment and prophylaxis of influenza infections.
MedKoo Cat#: 128540
Name: Suraxavir marboxil
CAS#: 2364589-86-4
Chemical Formula: C29H25F2N3O7S
Exact Mass: 597.1381
Molecular Weight: 597.59
Elemental Analysis: C, 58.29; H, 4.22; F, 6.36; N, 7.03; O, 18.74; S, 5.36
The following data is based on the product molecular weight 597.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
